Skip to content
Get alerts
GovInfoNow
Stop using now Drug recall · FDA · Published July 21, 2020

Ferring Stimate Nasal Spray Recall: Superpotent Drug Hazard

Ferring Pharmaceuticals recalls Stimate nasal spray due to superpotent drug risks. Check lot numbers and expiration dates for affected units.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-1506-2020DrugFerring ›
Take action

Contact the company

Recalling firmFerring Pharmaceuticals Inc100 Interpace Pkwy · Parsippany, NJ 07054-1149
✎ GovInfoNow plain-language explainer

Ferring Pharmaceuticals Inc is recalling STIMATE (desmopressin acetate) Nasal Spray because it is a superpotent drug. The product is available by prescription only and manufactured for CSL Behring LLC. This recall affects specific lots distributed nationwide within the United States. Read more at govinfonow.com/recall/36920-ferring-stimate-nasal-spray-recall-superpotent-drug-hazard.

Source Summary by GovInfoNow · govinfonow.com/recall/36920-ferring-stimate-nasal-spray-recall-superpotent-drug-hazard · Updated October 11, 2026 · FDA enforcement record: FDA #D-1506-2020

Cite this page

“Ferring Stimate Nasal Spray Recall: Superpotent Drug Hazard.” GovInfoNow, updated October 11, 2026. https://govinfonow.com/recall/36920-ferring-stimate-nasal-spray-recall-superpotent-drug-hazard. Based on FDA recall #D-1506-2020 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1506-2020%22&limit=1).

Ferring Pharmaceuticals Inc recalled STIMATE (desmopressin acetate) Nasal Spray due to superpotent drug classification issues, according to the FDA. The agency announced the recall on July 21, 2020.

How to tell if you have it

  • Brand: Ferring
  • Product: STIMATE (desmopressin acetate) Nasal Spray
  • Concentration/Volume: 1.5 mg/mL, 2.5 mL glass vial with spray cap
  • NDC: 0053-6871-00
  • Lot codes and expiration dates: N14134C (exp. 07 2020), N15378G (exp. 09 2020), N17445N (exp. 02 2020), P11326AA (exp. 02 2021), P11326C (exp. 02 2021), P13209L (exp. 04 2021), P13212H (exp. 06 2021), P13755A (exp. 06 2021), P13756P (exp. 08 2021), R11845A (exp. 04 2022), R13271A (exp. 04 2022), R13648A (exp. 06 2022), R14101A (exp. 07 2022), R14667A (exp. 08 2022), R15953C (exp. 09 2022)

The hazard

The recall is classified as a Class I hazard involving superpotent drug issues, according to the FDA.

Context

GovInfoNow's records show Ferring Pharmaceuticals Inc has 8 other recalls on record since 2012-08-23. Other recent recalls of similar products include Apotex Desmopressin Nasal Spray Recall (2026-04-08), Walgreens Saline Nasal Spray with Xylitol Recall (2025-11-12), and Beekeeper's Naturals Saline Nasal Spray Recall (2026-06-01).

How to tell if you have this one

Check your nasal spray vial for the NDC number 0053-6871-00. Verify the lot number and expiration date against the record: Lot N14134C (exp 07/2020), N15378G (exp 09/2020), N17445N (exp 02/2020), P11326AA (exp 02/2021), P11326C (exp 02/2021), P13209L (exp 04/2021), P13212H (exp 06/2021), P13755A (exp 06/2021), P13756P (exp 08/2021), R11845A (exp 04/2022), R13271A (exp 04/2022), R13648A (exp 06/2022), R14101A (exp 07/2022), or R15953C (exp 09/2022).

  • Brand
    Ferring
  • Category
    Drug
FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class I
  • Status
    Terminated
  • Distribution
    Nationwide within the United States.
Recall numberProduct, codes & lotsQuantity
D-1504-2020DDAVP Nasal Spray (desmopressin acetate) 10 mcg/0.1 mL, 5 mL bottles, Rx Only, Mfd for: Ferring Pharmaceuticals Inc., Parsippany, NJ 07054 USA, NDC 55566-2500-0; Lot #: N14695F, exp. date 08/2020 N15627C, exp. date 10/2020 P11319P, exp. date 01/2021 P11706F, exp. date 04/2021 R11842C, exp. date 03/2022; R13637E, exp. date 06/202215,175 nasal sprays
D-1505-2020Desmopressin Acetate Nasal Spray 10 mcg/0.1 mL, 5mL glass vial with spray cap, Rx only, Manufactured for: AMRING PHARMACEUTICALS INC., Berwyn, PA 19312, NDC 69918-501-05; Lot #: N14695P, N14695S, exp. date 08 2020; N15627G , exp. date 10 2020 N15627GA, exp. date 10 2020 P10422A, exp. date 01 2021 P10422AA, exp. date 01 2021 P10430G, exp. date 03 2021 P11319M, exp. date 01 2021 P12969H, exp. date 05 2021 P12969IR, exp. date 05 2021 P13216G, exp. date 05 2021 P13216P, exp. date 05 2021 R11842A, exp. date 03 2022 R11842S, exp. date 03 2022 R12630A, exp. date 05 2022 R13071H, exp. date 04 2022184,325 nasal sprays
D-1506-2020STIMATE (desmopressin acetate) Nasal Spray1.5 mg/mL, 2.5 mL glass vial with spray cap, Rx only, Manufactured for: CSL Behring LLC, King of Prussia, PA 19406-0901; By: Ferring GmbH, Kiel, Germany, NDC 0053-6871-00; Lot # N14134C, exp. date 07 2020 N15378G, exp. date 09 2020 N17445N, exp. date 02 2020 P11326AA, exp. date 02 2021 P11326C, exp. date 02 2021 P13209L, exp. date 04 2021 P13212H, exp. date 06 2021 P13755A, exp. date 06 2021 P13756P, exp. date 08 2021 R11845A, exp. date 04 2022 R13271A, exp. date 04 2022 R13648A, exp. date 06 2022 R14101A, exp. date 07 2022 R14667A, exp. date 08 2022 R15953C, exp. date 09 202229,371 nasal sprays
Based on the official FDA remedy

What to do — step by step

  1. Stop using the product

    Do not use any STIMATE nasal spray if it matches the lot numbers and expiration dates listed in the recall record.

  2. Contact your healthcare provider

    Speak with your doctor or pharmacist immediately to discuss alternative treatments or proper disposal methods for the recalled medication.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide within the United States.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 3.2 years after the firm started it.

1. Firm started the recall: Jul 21, 202012. FDA classified it Class I: Aug 17, 202023. Published in FDA’s Enforcement Report: Aug 26, 202034. FDA terminated the recall: Oct 13, 2023420202023
  1. Firm started the recall
  2. FDA classified it Class I
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Apotex Desmopressin Nasal Spray Recall: Defective Bottle Caps Risk
ApotexAmerican Health Packaging Recalls Metoclopramide Tablets Due to Foreign Drug Presence
American Health PackagingTeva Recalls Metoclopramide Tablets Due to Foreign Contaminants
Teva Pharmaceuticals USA, IncPreferred Pharma Recalls Lidocaine Ointment Due to Content Issues
Preferred Pharmaceuticals, Inc.Northstar Rx Recalls Tretinoin Cream Due to Impurities
SUN PHARMACEUTICAL INDUSTRIES INC

Latest drug recalls

Apothecary Pharma LLC recalls Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary,
Apothecary Pharma · September 24, 2026Apotex Corp. recalls Paroxetine Extended-Release Tablets, 37.5mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario,
Apotex · September 23, 2026Cipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral Solution, (Equivalent to 3 Grams of Fosfomycin), 1 Single-Dose Sachet, Rx
Cipla USA · September 18, 2026Ajanta Pharma USA Inc recalls Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc.,
Ajanta Pharma · September 17, 2026Insight Pharmaceuticals LLC, a Prestige Consumer Healthcare company recalls Clear Eyes Redness Relief, Lubricant/Redness Reliever Eye Drops (glycerin 0.25%, naphazoline hydrochloride 0.012%) with
Insight Pharmaceuticals · September 15, 2026K.C. Pharmaceuticals, Inc. recalls Sterile Lubricant Dry Eye Relief Eye Drops, 0.5 FL OZ (15 mL); a) LEADER, DISTRIBUTED BY CARDINAL HEALTH, DUBLIN, OHIO
Leader / TopCare / Crocodile Tears · September 11, 2026

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1506-2020 (July 21, 2020) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1506-2020 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 11, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA